Active Recombinant Rat Il9r, His-tagged

• Cat.No.: Il9r-538R
• Product Overview: Recombinant Rat Il9r (Accession # EDM04022) Val38-Ala270, fused with a C-terminal 6-His tag, was produced in Mouse myeloma cell line, NS0-derived.

Specification

• Source: Mammalian cells
• Species: Rat
• Tag: His
• Predicted N Terminal: Val38
• Form: Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein.
• Bio-activity: Measured by its ability to inhibit IL-9-induced proliferation of TS1 mouse helper T cells.The ED50 for this effect is typically 0.25 - 1.25 µg/mL in the presence of rrIL-9 at 50 ng/mL.
• Molecular Mass: Recombinant Rat Il9r, His-tagged has a calculated MW of 27.5 kDa. In SDS-PAGE migrates as 33-40 kDa, reducing conditions.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Storage: Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).
• Reconstitution: Reconstitute at 200 µg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
• Protein length: Val38-Ala270

Gene Information

• Gene Name: Il9r interleukin 9 receptor [ Rattus norvegicus ]
• Official Symbol: Il9r
• Synonyms: IL9R; interleukin 9 receptor; interleukin-9 receptor
• Gene ID: 24500
• mRNA Refseq: NM_017021
• Protein Refseq: NP_058717

Reviews

05/10/2022

IL9R is very advanced and adopts the most environmentally friendly production process, which is worth vigorously promoting.

01/11/2022

The reproducibility of IL9R is very good, and the results are very consistent in each experiment or application, thanks to its high stability and reproducibility, which provides great convenience for follow-up studies.

02/27/2020

IL9R produced by them are widely used and suitable for various biological experiments.

Q&As

Can the treatment of cancer with IL9R improve the immune system of patients?

In pre-clinical trials, the IL9R significantly increased natural killer and CD4 + T cell levels in patients.

What somatic cell therapy-based data updates can recombinant IL9R be used for?

IL9R may play an important role in the treatment of central nervous system diseases and hematological diseases.

In which tumor therapies are recombinant IL9R most likely to be effective?

This needs to be further confirmed by large-scale clinical trials.

What techniques are used to study the relationship between IL9R and cancer?

This can be achieved through in vitro molecular cell techniques and carefully designed in vivo animal models.

Which diseases might be treated by recombinant IL9R?

There have been no large-scale clinical studies to prove which diseases the recombinant IL9R protein can treat.

Is the expression of IL9R in tumor cells correlated with patient prognosis?

Some studies have suggested that the expression of IL9R in tumor cells may be associated with patient prognosis.